



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

DIVISION OF
CORPORATION FINANCE

December 1, 2010

Theodore R. Schroeder
President and CEO
Cadence Pharmaceuticals, Inc.
12481 High Bluff Dr., Suite 200
San Diego, CA 92130

**Re: Cadence Pharmaceuticals, Inc.
Form 10-K for the year ended December 31, 2009
Definitive Proxy Statement on Schedule 14A
Filed April 29, 2010
File No. 1-33103**

Dear Mr. Schroeder:

We have completed our review of your Form 10-K and related filings and do not have any further comments at this time.

Sincerely,

Gus Rodriguez
Branch Chief